Phio Pharmaceuticals Reported In-line with Estimates

Phio Pharmaceuticals (PHIO) reported a loss of $0.36 per share on revenue of $0.00 million for the second quarter ended June 2026. The consensus estimate was a loss of $0.36 per share. The company reported in-line with consensus estimates.

Phio Pharmaceuticals Corp is focused on developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi therapeutic platform. The Company's pipeline consists of RXI-762 and RXI-804 which are in clinical stage. Phio Pharmaceuticals Corp, formerly known as RXi Pharmaceuticals Corporation, is based in Marlborough, United States.